Clinical Trials

420 enrolled

Carcinoma, Transitional Cell

NCT05152147 2026-04-17

HERIZON-GEA-01

920 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT06151574 2026-04-15

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

416 enrolled

Lung Neoplasms

NCT02466971 2026-04-13

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

450 enrolled 11 charts

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT03775265 2026-04-13

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

475 enrolled

Urinary Bladder Neoplasms

NCT03811002 2026-04-13

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

544 enrolled 29 charts

Lung Neoplasms

NCT03811015 2026-04-13

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

636 enrolled

Oropharyngeal Neoplasms

NCT04092283 2026-04-13

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

660 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04658862 2026-04-13

SunRISe-2

518 enrolled

Urinary Bladder Neoplasms

NCT03772028 2026-04-08

OVHIPEC-2

538 enrolled

Gynecologic

Ovarian Neoplasms

NCT05911295 2026-04-07

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

412 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05261399 2026-04-06

SAFFRON

345 enrolled

Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02445391 2026-04-01

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

415 enrolled 15 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00980460 2026-03-31

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

236 enrolled 18 charts

PRETEXT I Hepatoblastoma

NCT04205812 2026-03-31

POD1UM-304

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04129502 2026-03-30

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

354 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05555732 2026-03-25

TROPION-Lung07

1,170 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05771480 2026-03-25

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

453 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

756 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT05687266 2026-03-13

AVANZAR

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 2 FDA

Urothelial Cancer

NCT05721755 2026-03-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

290 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

757 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

403 enrolled 10 charts

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT02453282 2026-03-02

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT07435324 2026-02-27

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

161 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03774732 2026-02-25

NIRVANA-LUNG

327 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02542293 2026-02-12

NEPTUNE

953 enrolled 29 charts

Non Small Cell Lung Carcinoma NSCLC

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

177 enrolled

Plasma cell

Multiple Myeloma

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03682068 2026-02-03

NILE

1,246 enrolled

Urinary Bladder Neoplasms

NCT03456076 2026-01-30

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

257 enrolled 14 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05502237 2026-01-30

STAR-121

1,021 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04550260 2026-01-29

KUNLUN

640 enrolled

Esophageal Squamous Cell Carcinoma

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT06564844 2026-01-27

TROPION-Lung12

24 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT06591520 2026-01-21

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

682 enrolled

Biliary Tract Neoplasms

NCT04914598 2026-01-02

A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

290 enrolled

Pleural Effusion, Malignant

NCT03533582 2025-12-22

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

537 enrolled

Fibrolamellar hepatocellular carcinoma, Hepatoblastoma

NCT04949256 2025-12-15

MK-7902-014

864 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05870319 2025-12-05

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

376 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02341989 2025-12-02

SWENOTECA-ABC

348 enrolled

Recurrence, Testicular Neoplasms, Seminoma

NCT04595565 2025-11-25

SASCIA

1,332 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04982237 2025-11-19

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer